Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Radiopharmaceuticals × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2 Tumor-Agnostic 1 Thoracic 1 Genitourinary 1 Endocrine 1 Breast 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 53 lutetium Lu 177 dotatate 44 Magnetic Resonance Spectroscopy 27 Cisplatin 26 Temozolomide 25 pembrolizumab 24 Octreotide 21 Nivolumab 21 lanreotide 20 gallium Ga 68 dotatate 19 cabozantinib 18 Specimen Handling 17 Capecitabine 17 Etoposide 16 pasireotide 15 lenvatinib 15 Paclitaxel 15 dabrafenib 14 Sunitinib 14 Carboplatin 14 Bevacizumab 14 trametinib 13 3-Iodobenzylguanidine 12 surufatinib 11 Ipilimumab 11 Injections 11 Doxorubicin 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Positron Emission Tomography Computed Tomography 10 Thyrotropin Alfa 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡